Absci Corporation

NasdaqGS ABSI

Absci Corporation Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 80.31 M

Absci Corporation Net Cash Used Provided By Financing Activities is USD 80.31 M for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Absci Corporation Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 2.55 M, a -99.37% change year over year.
Absci Corporation Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 401.88 M.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: ABSI

Absci Corporation

CEO	Mr. Sean McClain
IPO Date	July 22, 2021
Location	United States
Headquarters	18105 SE Mill Plain Boulevard
Employees	155
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Fintech

Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Key trends

Past 5 years